Schrödinger (NASDAQ:SDGR) Price Target Raised to $28.00

Schrödinger (NASDAQ:SDGR) had its price target lifted by BMO Capital Markets from $25.00 to $28.00 in a research report report published on Wednesday,Benzinga reports. The firm currently has an outperform rating on the stock.

Separately, Morgan Stanley reduced their price target on Schrödinger from $43.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Wednesday, August 21st. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $32.90.

Schrödinger Price Performance

Shares of Schrödinger stock opened at $18.54 on Wednesday. The firm has a 50 day simple moving average of $18.72 and a 200 day simple moving average of $20.35. Schrödinger has a fifty-two week low of $16.67 and a fifty-two week high of $38.00.

Schrödinger (NASDAQ:SDGR) last released its earnings results on Tuesday, November 12th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.12). The firm had revenue of $35.30 million for the quarter, compared to the consensus estimate of $41.25 million. Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. The company’s revenue was down 17.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.86) EPS. On average, analysts expect that Schrödinger will post -2.29 EPS for the current year.

Insider Buying and Selling

In other news, insider Margaret Dugan sold 1,531 shares of the firm’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $17.78, for a total transaction of $27,221.18. Following the completion of the transaction, the insider now directly owns 13,469 shares of the company’s stock, valued at $239,478.82. This trade represents a 10.21 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 8.60% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Harbor Capital Advisors Inc. grew its holdings in shares of Schrödinger by 5.0% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 13,059 shares of the company’s stock valued at $242,000 after acquiring an additional 622 shares in the last quarter. Texas Permanent School Fund Corp grew its stake in Schrödinger by 1.3% in the first quarter. Texas Permanent School Fund Corp now owns 47,869 shares of the company’s stock valued at $1,292,000 after purchasing an additional 626 shares in the last quarter. Louisiana State Employees Retirement System increased its position in shares of Schrödinger by 2.6% during the 2nd quarter. Louisiana State Employees Retirement System now owns 27,800 shares of the company’s stock worth $538,000 after purchasing an additional 700 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Schrödinger by 49.5% during the 2nd quarter. GAMMA Investing LLC now owns 2,124 shares of the company’s stock worth $41,000 after purchasing an additional 703 shares in the last quarter. Finally, ProShare Advisors LLC boosted its holdings in shares of Schrödinger by 7.4% in the 1st quarter. ProShare Advisors LLC now owns 10,987 shares of the company’s stock valued at $297,000 after buying an additional 753 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Schrödinger Company Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.